Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma

被引：0
|
作者：
Lokhorst, Henk M.
Plesner, Torben
Gimsing, Peter
Nahi, Hareth
Minnema, Monique
Lassen, Ulrik Niels
Krejcik, Jakub
Laubach, Jacob
Lisby, Steen
Basse, Linda
Richardson, Paul Gerard Guy
机构：
[1] UMC Utrecht, Utrecht, Netherlands
[2] Vejle Hosp, Vejle, Denmark
[3] Copenhagen Univ Hosp, Copenhagen, Denmark
[4] Karolinska Univ, Sjukhuset Huddinge, Huddinge, Sweden
[5] Rigshosp, DK-2100 Copenhagen, Denmark
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA
[7] Genmab AS, Copenhagen, Denmark
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8512
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study
    Kumar, Shaji K.
    Krishnan, Amrita
    Roy, Vivek
    Zimmerman, Todd M.
    Gertz, Morie Abraham A.
    Stockerl-Goldstein, Keith E.
    Buadi, Francis K.
    Rosenbaum, Cara
    Birgin, Ann
    Fiala, Mark
    Jiminez, Valeria
    Maharaj, Michele
    Needle, Michael N.
    Vij, Ravi
    BLOOD, 2012, 120 (21)
  • [32] A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
    Berenson, James R.
    Klein, Leonard
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Ou, Ying
    Cartmell, Alan
    BLOOD, 2013, 122 (21)
  • [33] Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
    Ja Min Byun
    Chang-Ki Min
    Kihyun Kim
    Soo-Mee Bang
    Je-Jung Lee
    Jin Seok Kim
    Sung-Soo Yoon
    Youngil Koh
    Journal of Hematology & Oncology, 15
  • [34] Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
    Byun, Ja Min
    Min, Chang-Ki
    Kim, Kihyun
    Bang, Soo-Mee
    Lee, Je-Jung
    Kim, Jin Seok
    Yoon, Sung-Soo
    Koh, Youngil
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [35] Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
    Dinner, Shira N.
    Dunn, Tamara J.
    Medeiros, Bruno C.
    Coutre, Steven E.
    Berube, Caroline
    Gotlib, Jason
    Liedtke, Michaela
    BLOOD, 2012, 120 (21)
  • [36] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
  • [37] A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Gonsalves, Wilson, I
    Neparidze, Natalia
    Allred, Jacob B.
    Kumar, Shaji K.
    Reid, Joel M.
    Shapiro, Geoffrey
    Costello, Brian A.
    Piekarz, Richard
    Baz, Rachid C.
    Devarakonda, Srinivas
    BLOOD, 2022, 140 : 7315 - 7316
  • [38] A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/ Refractory Multiple Myeloma
    Chari, Ajai
    Htut, Myo
    Zonder, Jeffrey A.
    Fay, Joseph W.
    Jakubowiak, Andrzej J.
    Levy, Joan B.
    Lau, Kenneth
    Burt, Steven M.
    Tunquist, Brian J.
    Hilder, Brandi W.
    Rush, Selena A.
    Walker, Duncan H.
    Ptaszynski, Mieke
    Kaufman, Jonathan L.
    CANCER, 2016, 122 (21) : 3327 - 3335
  • [39] Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma.
    Lust, John Anthony
    Barranco, Charles
    Lacy, Martha
    Dispenzieri, Angela
    Gertz, Morie A.
    Dingli, David
    Russell, Stephen J.
    Buadi, Francis
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Kumar, Shaji
    Usmani, Saad Zafar
    Thompson, John
    Taylor, Catherine
    Dondero, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma
    Kumar, Anita
    Blum, Kristie A.
    Fung, Henry C.
    Smith, Mitchell R.
    Foster, Paul A.
    Younes, Anas
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 902 - 904
12345